Lutris wins FDA orphan drug tag for EGFR inhibitor-induced rash candidate
Pharmaceutical Technology
FEBRUARY 29, 2024
LUT014 is being investigated in an ongoing Phase II trial as a first-line treatment for EGFR inhibitor-induced acneiform rash, for which there is no approved drug.
Let's personalize your content